Resource library: Reagent resource for studying SARS-CoV-2 variants
Posted: 23 February 2021 | Sino Biological Inc. | No comments yet
Sino Biological has developed 80+ mutant proteins covering the newest mutations identified in SARS-CoV-2 variants, such as UK’s B.1.1.7, Brazil’s P.1.
Sino Biological has developed 80+ recombinant RBD/Spike and Nucleocapsid protein mutants carrying the mutations of high interest, such as N501Y and E484K identified in three new fast-spreading SARS-CoV-2 variants, UK’s B.1.1.7, Brazil’s P.1, and South Africa’s B.1.351, emerging in recent months, to support evaluating the efficacy of the antibodies and vaccination.
Related content from this organisation
Related topics
Antibodies, Biomarkers, Biopharmaceuticals, Disease research, Immunology
Related organisations
Sino Biological Inc.